Praxis Precision Medicines (NASDAQ:PRAX) Posts Earnings Results, Beats Estimates By $0.80 EPS
One daysingle sourceOne outlet reported this, once - no second voice in this corpus.
All 1 reports on Thu, 6 August 2026
What it is about
Jill DesimoneRoyal BankGroup PlcPraxis Precision Medicines Company ProfileSecurities Exchange CommissionJefferies Financial GroupNasdaqDeutsche Bank AktiengesellschaftTower Research CapitalCanadaLos Angeles, California, United States
Who published it, and when
How it spread - 1 original report
Thu, 6 August 2026
1 report- dailypolitical.com21:57first to report
Praxis Precision Medicines (NASDAQ:PRAX – Get Free Report) posted its quarterly earnings results on Thursday. The company reported ($2.87) EPS for the quarter, topping analysts’ consensus estimates of ($3.67) by $0.80, FiscalAI reports. Here are the key takeaways from Praxis Precision Medicines’ conference call: Ulixacaltamide and relutrigine remain on track for potential FDA decisions, with […]